Compare Charles River Laboratories Intl. Inc (CRL) vs NIO Inc. (NIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs NIO Inc. — how do they compare? Charles River Laboratories Intl. Inc trades at $302.66 (market cap $14.23B), while NIO Inc. trades at $3.59 (market cap $8.62B). The key difference: Charles River Laboratories Intl. Inc is the larger of the two by market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, NIO Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and NIO Inc. for 81 Days on average.
| CRL | NIO | |
|---|---|---|
Market Cap | $14.23B | $8.62B |
Volume | 1,176,885 | 39,648,517 |
Sector | Health | Consumer Cyclical |
52-Week High | $310.77 | $7.46 |
52-Week Low | $149.93 | $3.37 |
Typical Hold Time | 33 Days | 81 Days |
Enterprise Value | $17.06B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.
NIO trades at $3.60, up 1.69% today but near 52-week lows, with technical indicators showing bearish momentum. The company reported Q3 2026 deliveries up 25.4% and recently completed a strategic battery-swapping partnership with Geely. Despite revenue growth to $87.49B in 2025, NIO continues to post significant losses with a -17.8% net margin. Analyst consensus remains positive with a $6.23 price target, though technical signals and cash flow challenges present headwinds.
NIO's growth trajectory and strategic partnerships offer long-term potential, but investors face substantial execution risks amid persistent losses and competitive pressures. The stock's current discount to analyst targets presents opportunity, but requires careful monitoring of profitability improvements and market share sustainability in the crowded EV sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
